Industry
Medical - Devices
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Loading...
Open
1.30
Mkt cap
2.9M
Volume
130K
High
1.38
P/E Ratio
-0.08
52-wk high
10.56
Low
1.30
Div yield
N/A
52-wk low
0.80
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 12:08 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 2:15 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 12:32 pm
Portfolio Pulse from Avi Kapoor
July 25, 2024 | 10:36 am
Portfolio Pulse from Avi Kapoor
July 24, 2024 | 5:26 pm
Portfolio Pulse from Avi Kapoor
July 24, 2024 | 2:17 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 2:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:55 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:53 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 1:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.